

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/EBC5B77E746EN.html
Date:	May 9, 2017
Pages:	59
Price:	US\$ 125.00
ID:	EBC5B77E746EN

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

Exelixis Inc Key Recent Developments

May 01,2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update

Mar 29,2017: Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan

Feb 27,2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides

Corporate Update

Jan 09,2017: Genentech withdraws counterclaim against Exelixis

Nov 03,2016: Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Exelixis Inc - Key Facts

Exelixis Inc - Key Employees

Exelixis Inc - Key Employee Biographies

Exelixis Inc - Major Products and Services

Exelixis Inc - Pharmaceutical Pipeline Products Data

Exelixis Inc, Pipeline Products by Therapy Area

Exelixis Inc, Pipeline Products by Development Phase

Exelixis Inc - History

Exelixis Inc - Company Statement

Exelixis Inc - Locations And Subsidiaries

Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Exelixis Inc - Business Description
Exelixis Inc - Corporate Strategy
Exelixis Inc - SWOT Analysis
SWOT Analysis - Overview
Exelixis Inc - Strengths
Exelixis Inc - Weaknesses
Exelixis Inc - Opportunities
Exelixis Inc - Threats
Exelixis Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Exelixis Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

May 01, 2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update
Feb 27, 2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis
Nov 03, 2016: Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
Sep 26, 2016: Exelixis Elects Julie Anne Smith to Its Board of Directors
Aug 03, 2016: Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
May 04, 2016: Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update
Feb 29, 2016: Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Exelixis Inc, Key Facts
Exelixis Inc, Key Employees
Exelixis Inc, Key Employee Biographies
Exelixis Inc, Major Products and Services
Exelixis Inc, Number of Pipeline Products by Therapy Area
Exelixis Inc, Number of Pipeline Products by Development Stage
Exelixis Inc, History
Exelixis Inc, Subsidiaries
Exelixis Inc, Key Competitors
Exelixis Inc, Ratios based on current share price
Exelixis Inc, Annual Ratios
Exelixis Inc, Annual Ratios (Cont.1)
Exelixis Inc, Annual Ratios (Cont.2)
Exelixis Inc, Interim Ratios
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Exelixis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Exelixis Inc, Pipeline Products by Therapy Area
Exelixis Inc, Pipeline Products by Development Phase
Exelixis Inc, Performance Chart (2012 - 2016)
Exelixis Inc, Ratio Charts
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Sevion Therapeutics Inc
Intercept Pharmaceuticals Inc
Ignyta Inc
Genentech Inc
Astex Pharmaceuticals Inc
Array BioPharma Inc

I would like to order:

Product name: Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/EBC5B77E746EN.html>
Product ID: EBC5B77E746EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/EBC5B77E746EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**